Serum galectin‐3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer
Galectin‐3 plays an important role in cell‐cell adhesion, macrophage activation, angiogenesis, metastasis and apoptosis and is overexpressed in pancreatic cancer. We explored the importance of galectin‐3 in the screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic can...
Gespeichert in:
| Veröffentlicht in: | Journal of cellular and molecular medicine 2020-10, Vol.24 (19), p.11583-11591 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 11591 |
|---|---|
| container_issue | 19 |
| container_start_page | 11583 |
| container_title | Journal of cellular and molecular medicine |
| container_volume | 24 |
| creator | Yi, Nan Zhao, Xuying Ji, Jie Xu, Minxue Jiao, Yujie Qian, Tianyang Zhu, Shengze Jiang, Feng Chen, Jianhua Xiao, Mingbing |
| description | Galectin‐3 plays an important role in cell‐cell adhesion, macrophage activation, angiogenesis, metastasis and apoptosis and is overexpressed in pancreatic cancer. We explored the importance of galectin‐3 in the screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer. A time‐resolved fluorescence immunoassay was performed to detect serum galectin‐3 level. Serum samples were collected from healthy controls and patients with pancreatic cancer before and after different treatments, and the relationships between galectin‐3 level and clinical parameters were analysed. Among the healthy controls, one individual with an abnormally high concentration of galectin‐3 (9.85 μg/L) was diagnosed with pancreatic cancer. Compared to the pre‐operative level, galectin‐3 concentration significantly decreased in patients with radical excision 1 month after surgery (P |
| doi_str_mv | 10.1111/jcmm.15775 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7576229</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2452315797</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4485-4744c0c4d64cf6bce5d36f5dd37b0356db0ca9f477337f0ace2b2895cec511ce3</originalsourceid><addsrcrecordid>eNp9kcuKFDEUhoMozji68QEk4EZkesy1UrURpPHKDC7UdUilTnrSViU1SdVI78Qn8Bl9EtNWO6gLs8kP5-PjHH6EHlJyRst7trXDcEalUvIWOqayZivRcHH7kGnN6yN0L-ctIbyivLmLjjir60owcYy-fYA0D3hjerCTDz--fufYZGxw6-Ng0mdI2MWEs00AwYfNKQaT-h3uvNmEmH0-xWOKS8QmdHi6hGRGmCdvMThXrBiuTT-byceAo8OjCUVm9nNbIqT76I4zfYYHh_8EfXr18uP6zer8_eu36xfnKytELVdCCWGJFV0lrKtaC7LjlZNdx1VLuKy6lljTOKEU58oRY4G1rG6kBSsptcBP0PPFO87tAJ2FMCXT6zH5cuhOR-P135PgL_UmXmslVcVYUwRPDoIUr2bIkx58ttD3JkCcs2ZCEKFIU9OCPv4H3cY5hXJeoSTjpa1GFerpQtkUc07gbpahRO-r1ftq9a9qC_zoz_Vv0N9dFoAuwBffw-4_Kv1ufXGxSH8Cn2ay5Q</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2452315797</pqid></control><display><type>article</type><title>Serum galectin‐3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer</title><source>MEDLINE</source><source>Wiley Journals</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Wiley Online Library (Open Access Collection)</source><source>PubMed Central</source><creator>Yi, Nan ; Zhao, Xuying ; Ji, Jie ; Xu, Minxue ; Jiao, Yujie ; Qian, Tianyang ; Zhu, Shengze ; Jiang, Feng ; Chen, Jianhua ; Xiao, Mingbing</creator><creatorcontrib>Yi, Nan ; Zhao, Xuying ; Ji, Jie ; Xu, Minxue ; Jiao, Yujie ; Qian, Tianyang ; Zhu, Shengze ; Jiang, Feng ; Chen, Jianhua ; Xiao, Mingbing</creatorcontrib><description>Galectin‐3 plays an important role in cell‐cell adhesion, macrophage activation, angiogenesis, metastasis and apoptosis and is overexpressed in pancreatic cancer. We explored the importance of galectin‐3 in the screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer. A time‐resolved fluorescence immunoassay was performed to detect serum galectin‐3 level. Serum samples were collected from healthy controls and patients with pancreatic cancer before and after different treatments, and the relationships between galectin‐3 level and clinical parameters were analysed. Among the healthy controls, one individual with an abnormally high concentration of galectin‐3 (9.85 μg/L) was diagnosed with pancreatic cancer. Compared to the pre‐operative level, galectin‐3 concentration significantly decreased in patients with radical excision 1 month after surgery (P < .05), but showed no obvious change in patients who underwent palliative resection. Additionally, among patients with radical excision, carcinoma recurrence rate was significantly higher in those with increased or unchanged galectin‐3 level. Retrospective analysis revealed the extraordinarily high value and high specificity of galectin‐3 for predicting 3‐year survival (P < .001). Thus, galectin‐3 may serve as a potential biomarker for the screening and early diagnosis of pancreatic cancer and as an independent prognostic indicator in patients with pancreatic cancer.</description><identifier>ISSN: 1582-1838</identifier><identifier>EISSN: 1582-4934</identifier><identifier>DOI: 10.1111/jcmm.15775</identifier><identifier>PMID: 32886424</identifier><language>eng</language><publisher>England: John Wiley & Sons, Inc</publisher><subject>Adolescent ; Adult ; Aged ; Angiogenesis ; Antibodies ; Antigens ; Apoptosis ; Biomarkers ; Biomarkers, Tumor - blood ; Cancer therapies ; Case-Control Studies ; Cell activation ; Cell adhesion ; Cell adhesion & migration ; Chemotherapy ; Diagnosis ; Early Detection of Cancer ; Female ; Galectin 3 - blood ; galectin‐3 ; Hospitals ; Humans ; Lymphatic system ; Macrophages ; Male ; Medical prognosis ; Metastases ; Metastasis ; Middle Aged ; Multivariate Analysis ; Neoplasm Metastasis ; Neoplasm Recurrence, Local - pathology ; Original ; Palliative Care ; Pancreatic cancer ; Pancreatic Neoplasms - blood ; Pancreatic Neoplasms - diagnosis ; Pancreatic Neoplasms - therapy ; Patients ; Prognosis ; Proportional Hazards Models ; ROC Curve ; screening ; Statistical analysis ; Surgery ; Survival Analysis ; Thyroid gland ; Tumors ; Young Adult</subject><ispartof>Journal of cellular and molecular medicine, 2020-10, Vol.24 (19), p.11583-11591</ispartof><rights>2020 The Authors. published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.</rights><rights>2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4485-4744c0c4d64cf6bce5d36f5dd37b0356db0ca9f477337f0ace2b2895cec511ce3</citedby><cites>FETCH-LOGICAL-c4485-4744c0c4d64cf6bce5d36f5dd37b0356db0ca9f477337f0ace2b2895cec511ce3</cites><orcidid>0000-0002-2452-463X</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576229/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576229/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,1417,11562,27924,27925,45574,45575,46052,46476,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32886424$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yi, Nan</creatorcontrib><creatorcontrib>Zhao, Xuying</creatorcontrib><creatorcontrib>Ji, Jie</creatorcontrib><creatorcontrib>Xu, Minxue</creatorcontrib><creatorcontrib>Jiao, Yujie</creatorcontrib><creatorcontrib>Qian, Tianyang</creatorcontrib><creatorcontrib>Zhu, Shengze</creatorcontrib><creatorcontrib>Jiang, Feng</creatorcontrib><creatorcontrib>Chen, Jianhua</creatorcontrib><creatorcontrib>Xiao, Mingbing</creatorcontrib><title>Serum galectin‐3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer</title><title>Journal of cellular and molecular medicine</title><addtitle>J Cell Mol Med</addtitle><description>Galectin‐3 plays an important role in cell‐cell adhesion, macrophage activation, angiogenesis, metastasis and apoptosis and is overexpressed in pancreatic cancer. We explored the importance of galectin‐3 in the screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer. A time‐resolved fluorescence immunoassay was performed to detect serum galectin‐3 level. Serum samples were collected from healthy controls and patients with pancreatic cancer before and after different treatments, and the relationships between galectin‐3 level and clinical parameters were analysed. Among the healthy controls, one individual with an abnormally high concentration of galectin‐3 (9.85 μg/L) was diagnosed with pancreatic cancer. Compared to the pre‐operative level, galectin‐3 concentration significantly decreased in patients with radical excision 1 month after surgery (P < .05), but showed no obvious change in patients who underwent palliative resection. Additionally, among patients with radical excision, carcinoma recurrence rate was significantly higher in those with increased or unchanged galectin‐3 level. Retrospective analysis revealed the extraordinarily high value and high specificity of galectin‐3 for predicting 3‐year survival (P < .001). Thus, galectin‐3 may serve as a potential biomarker for the screening and early diagnosis of pancreatic cancer and as an independent prognostic indicator in patients with pancreatic cancer.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Angiogenesis</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Apoptosis</subject><subject>Biomarkers</subject><subject>Biomarkers, Tumor - blood</subject><subject>Cancer therapies</subject><subject>Case-Control Studies</subject><subject>Cell activation</subject><subject>Cell adhesion</subject><subject>Cell adhesion & migration</subject><subject>Chemotherapy</subject><subject>Diagnosis</subject><subject>Early Detection of Cancer</subject><subject>Female</subject><subject>Galectin 3 - blood</subject><subject>galectin‐3</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Lymphatic system</subject><subject>Macrophages</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Metastasis</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Original</subject><subject>Palliative Care</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - blood</subject><subject>Pancreatic Neoplasms - diagnosis</subject><subject>Pancreatic Neoplasms - therapy</subject><subject>Patients</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>ROC Curve</subject><subject>screening</subject><subject>Statistical analysis</subject><subject>Surgery</subject><subject>Survival Analysis</subject><subject>Thyroid gland</subject><subject>Tumors</subject><subject>Young Adult</subject><issn>1582-1838</issn><issn>1582-4934</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><recordid>eNp9kcuKFDEUhoMozji68QEk4EZkesy1UrURpPHKDC7UdUilTnrSViU1SdVI78Qn8Bl9EtNWO6gLs8kP5-PjHH6EHlJyRst7trXDcEalUvIWOqayZivRcHH7kGnN6yN0L-ctIbyivLmLjjir60owcYy-fYA0D3hjerCTDz--fufYZGxw6-Ng0mdI2MWEs00AwYfNKQaT-h3uvNmEmH0-xWOKS8QmdHi6hGRGmCdvMThXrBiuTT-byceAo8OjCUVm9nNbIqT76I4zfYYHh_8EfXr18uP6zer8_eu36xfnKytELVdCCWGJFV0lrKtaC7LjlZNdx1VLuKy6lljTOKEU58oRY4G1rG6kBSsptcBP0PPFO87tAJ2FMCXT6zH5cuhOR-P135PgL_UmXmslVcVYUwRPDoIUr2bIkx58ttD3JkCcs2ZCEKFIU9OCPv4H3cY5hXJeoSTjpa1GFerpQtkUc07gbpahRO-r1ftq9a9qC_zoz_Vv0N9dFoAuwBffw-4_Kv1ufXGxSH8Cn2ay5Q</recordid><startdate>202010</startdate><enddate>202010</enddate><creator>Yi, Nan</creator><creator>Zhao, Xuying</creator><creator>Ji, Jie</creator><creator>Xu, Minxue</creator><creator>Jiao, Yujie</creator><creator>Qian, Tianyang</creator><creator>Zhu, Shengze</creator><creator>Jiang, Feng</creator><creator>Chen, Jianhua</creator><creator>Xiao, Mingbing</creator><general>John Wiley & Sons, Inc</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>WIN</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QP</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2P</scope><scope>M7P</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2452-463X</orcidid></search><sort><creationdate>202010</creationdate><title>Serum galectin‐3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer</title><author>Yi, Nan ; Zhao, Xuying ; Ji, Jie ; Xu, Minxue ; Jiao, Yujie ; Qian, Tianyang ; Zhu, Shengze ; Jiang, Feng ; Chen, Jianhua ; Xiao, Mingbing</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4485-4744c0c4d64cf6bce5d36f5dd37b0356db0ca9f477337f0ace2b2895cec511ce3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Angiogenesis</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Apoptosis</topic><topic>Biomarkers</topic><topic>Biomarkers, Tumor - blood</topic><topic>Cancer therapies</topic><topic>Case-Control Studies</topic><topic>Cell activation</topic><topic>Cell adhesion</topic><topic>Cell adhesion & migration</topic><topic>Chemotherapy</topic><topic>Diagnosis</topic><topic>Early Detection of Cancer</topic><topic>Female</topic><topic>Galectin 3 - blood</topic><topic>galectin‐3</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Lymphatic system</topic><topic>Macrophages</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Metastasis</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Original</topic><topic>Palliative Care</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - blood</topic><topic>Pancreatic Neoplasms - diagnosis</topic><topic>Pancreatic Neoplasms - therapy</topic><topic>Patients</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>ROC Curve</topic><topic>screening</topic><topic>Statistical analysis</topic><topic>Surgery</topic><topic>Survival Analysis</topic><topic>Thyroid gland</topic><topic>Tumors</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yi, Nan</creatorcontrib><creatorcontrib>Zhao, Xuying</creatorcontrib><creatorcontrib>Ji, Jie</creatorcontrib><creatorcontrib>Xu, Minxue</creatorcontrib><creatorcontrib>Jiao, Yujie</creatorcontrib><creatorcontrib>Qian, Tianyang</creatorcontrib><creatorcontrib>Zhu, Shengze</creatorcontrib><creatorcontrib>Jiang, Feng</creatorcontrib><creatorcontrib>Chen, Jianhua</creatorcontrib><creatorcontrib>Xiao, Mingbing</creatorcontrib><collection>Wiley Online Library (Open Access Collection)</collection><collection>Wiley Online Library (Open Access Collection)</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Science Database</collection><collection>Biological Science Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Access via ProQuest (Open Access)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cellular and molecular medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yi, Nan</au><au>Zhao, Xuying</au><au>Ji, Jie</au><au>Xu, Minxue</au><au>Jiao, Yujie</au><au>Qian, Tianyang</au><au>Zhu, Shengze</au><au>Jiang, Feng</au><au>Chen, Jianhua</au><au>Xiao, Mingbing</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Serum galectin‐3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer</atitle><jtitle>Journal of cellular and molecular medicine</jtitle><addtitle>J Cell Mol Med</addtitle><date>2020-10</date><risdate>2020</risdate><volume>24</volume><issue>19</issue><spage>11583</spage><epage>11591</epage><pages>11583-11591</pages><issn>1582-1838</issn><eissn>1582-4934</eissn><abstract>Galectin‐3 plays an important role in cell‐cell adhesion, macrophage activation, angiogenesis, metastasis and apoptosis and is overexpressed in pancreatic cancer. We explored the importance of galectin‐3 in the screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer. A time‐resolved fluorescence immunoassay was performed to detect serum galectin‐3 level. Serum samples were collected from healthy controls and patients with pancreatic cancer before and after different treatments, and the relationships between galectin‐3 level and clinical parameters were analysed. Among the healthy controls, one individual with an abnormally high concentration of galectin‐3 (9.85 μg/L) was diagnosed with pancreatic cancer. Compared to the pre‐operative level, galectin‐3 concentration significantly decreased in patients with radical excision 1 month after surgery (P < .05), but showed no obvious change in patients who underwent palliative resection. Additionally, among patients with radical excision, carcinoma recurrence rate was significantly higher in those with increased or unchanged galectin‐3 level. Retrospective analysis revealed the extraordinarily high value and high specificity of galectin‐3 for predicting 3‐year survival (P < .001). Thus, galectin‐3 may serve as a potential biomarker for the screening and early diagnosis of pancreatic cancer and as an independent prognostic indicator in patients with pancreatic cancer.</abstract><cop>England</cop><pub>John Wiley & Sons, Inc</pub><pmid>32886424</pmid><doi>10.1111/jcmm.15775</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-2452-463X</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1582-1838 |
| ispartof | Journal of cellular and molecular medicine, 2020-10, Vol.24 (19), p.11583-11591 |
| issn | 1582-1838 1582-4934 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7576229 |
| source | MEDLINE; Wiley Journals; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; Wiley Online Library (Open Access Collection); PubMed Central |
| subjects | Adolescent Adult Aged Angiogenesis Antibodies Antigens Apoptosis Biomarkers Biomarkers, Tumor - blood Cancer therapies Case-Control Studies Cell activation Cell adhesion Cell adhesion & migration Chemotherapy Diagnosis Early Detection of Cancer Female Galectin 3 - blood galectin‐3 Hospitals Humans Lymphatic system Macrophages Male Medical prognosis Metastases Metastasis Middle Aged Multivariate Analysis Neoplasm Metastasis Neoplasm Recurrence, Local - pathology Original Palliative Care Pancreatic cancer Pancreatic Neoplasms - blood Pancreatic Neoplasms - diagnosis Pancreatic Neoplasms - therapy Patients Prognosis Proportional Hazards Models ROC Curve screening Statistical analysis Surgery Survival Analysis Thyroid gland Tumors Young Adult |
| title | Serum galectin‐3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A29%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Serum%20galectin%E2%80%903%20as%20a%20biomarker%20for%20screening,%20early%20diagnosis,%20prognosis%20and%20therapeutic%20effect%20evaluation%20of%20pancreatic%20cancer&rft.jtitle=Journal%20of%20cellular%20and%20molecular%20medicine&rft.au=Yi,%20Nan&rft.date=2020-10&rft.volume=24&rft.issue=19&rft.spage=11583&rft.epage=11591&rft.pages=11583-11591&rft.issn=1582-1838&rft.eissn=1582-4934&rft_id=info:doi/10.1111/jcmm.15775&rft_dat=%3Cproquest_pubme%3E2452315797%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2452315797&rft_id=info:pmid/32886424&rfr_iscdi=true |